Bristol-Myers Squibb has one of the deepest immuno-oncology drug pipelines, with checkpoint inhibitors, T cell and natural killer cell agonists, and metabolic modulators of the tumour microenvironment. Despite a setback with its marketed checkpoint inhibitor nivolumab in a first-line lung cancer setting last year, there are still high hopes for these emerging therapies. In March, the company hired Thomas Lynch — former CEO of Massachusetts General Physicians Organization and Director of the Yale Cancer Center — as its new Chief Scientific Officer, tasked with overseeing the progress of this pipeline. He told Asher Mullard about his R&D priorities, the promise of genomic-based diagnostics and the need for faster development of novel cancer drugs in earlier stages of disease.

中文翻译：

---

托马斯·林奇

百时美施贵宝（Bristol-Myers Squibb）拥有最深入的免疫肿瘤药物研发渠道之一，具有检查点抑制剂，T细胞和自然杀伤细胞激动剂以及肿瘤微环境的代谢调节剂。尽管去年上市的检查点抑制剂尼古鲁单抗在第一线肺癌中遭受挫折，但对于这些新兴疗法仍然寄予厚望。3月，该公司聘用了麻省总医师组织前首席执行官，耶鲁癌症中心主任托马斯·林奇（Thomas Lynch）作为其新的首席科学官，负责监督这条管道的进度。他向Asher Mullard讲述了他的研发重点，基于基因组学的诊断方法的前景以及对疾病早期阶段新型癌症药物的更快开发的需求。